CAESAREA, Israel, May 17, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it signed global life sciences and consumer health executive, Olivier Jarry, to a Strategic Advisory role. Having managed innovation at the crossroads of technology, healthcare, and patient-centricity for three decades on five continents, Mr. Jarry brings a wealth of experience to DarioHealth.
Mr. Jarry was tapped for this position specifically because he has made key impacts in executive roles at companies like Bayer Diabetes, Bristol-Myers Squibb, and Novartis. In addition, he also serves as an advisor at Fit4D, a company that empowers people with diabetes to live towards optimal health.
DarioHealth is an integrated care company currently focusing on diabetes. Today's appointment allows DarioHealth to pursue additional avenues that will focus on improving better clinical outcomes for its users.
Erez Raphael, Chairman and CEO of DarioHealth, commented about the appointment, "Mr. Jarry has over 30 years of experience in improving health and living standards for people throughout the world. DarioHealth is dedicated to helping people with diabetes and Mr. Jarry compliments our advisory team. We look forward to working with him to capitalize on his vast knowledge ranging from big data techniques to developing new products and opportunities with added-value."
Olivier Jarry said, "DarioHealth has a unique, user-centric digital solution that attracts and retains people who want to better manage their chronic condition. There is no doubt that the market will transform from pure monitoring to integrated care, and DarioHealth is at the forefront of this tectonic shift. I believe that DarioHealth has the right solution and will apply it to the broader diabetes management ecosystem."
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes the impact of Mr. Jarry's appointment, and that the market will transform from pure monitoring to integrated care, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate and Media Contact
="file://10.86.178.61/Users/leah.st/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/6Z27PZHNfirstname.lastname@example.org" rel="nofollow" target="_blank">email@example.com
DarioHealth Investor Relations Contact
Rob Fink / Brett Maas
646-415-8972 / 646-536-7331
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dariohealth-adds-former-bayer-diabetes-executive-and-visionary-to-its-advisory-board-300459185.html
SOURCE DarioHealth Corp.